2BMonthly

Executives share insight on what product categories they anticipate will drive the most growth in the next 10 years in biologicals.

Executives share insight into whether the tremendous market growth in LATAM is scalable for the biologicals industry.

Biological executives share whether they have felt any impact from the regulatory slowdown stemming from the U.S. Endangered Species Act.

A panel of Brazilian thought leaders share their well-informed perspectives on the new law and its widespread implications.

Experts share insight on whether any actual improvements have been made with regulations for biologicals in Europe.

Executives offer their views on investment expectations for biologicals in the short to medium term.

From formulation to manufacturing, experts share their insight on where we can expect the industry’s greatest innovations.

The biologicals market was booming for many businesses in 2024. Executives share how their companies performed this past year.

Experts share insight on where they see this trend heading amid innovations in application and release systems.

Bioherbicides are the “Holy Grail” of biopesticides. Experts discuss when we’ll see new solutions enter the market.

The biologicals regulatory situation in the EU remains murky at best. Executives share their position on the matter.

Increased prices of raw materials have strongly impacted biostimulants production. Executives share how they’ve approached this issue.

Biologicals have made big gains in row crops in Brazil. Experts weigh in on what it will take to see a similar trend elsewhere.

Experts share what the most important factors are in successfully scaling a biological company and why some businesses fail.

After 2023 saw a number of large M&A deals, experts share whether that will continue in 2024 or start to decline.

With dramatically lower farm income reported in 2023, experts share their thoughts on how growers will invest in biologicals in 2024.